76.45
+0.98(+1.30%)
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
620
First IPO Date
June 16, 2020
| Name | Title | Pay | Year Born |
| Mr. Wennian Wu | Vice President, Chief Financial Officer, Secretary of the Board & Director | 0 | 1983 |
| Mr. Hongbo Wu | President & Non-Independent Director | 0 | 1968 |
| Mr. Huaigong Chen | Vice President & Quality Manager | 0 | 1972 |
| Mr. Fu Wang | Vice President | 0 | 1969 |
| Mr. Wanfeng Sun | Vice President | 0 | 1979 |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.